Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients.
نویسندگان
چکیده
haematologica/journal of hematology vol. 88(05):may 2003 597 associated with intracellular redox changes and elevated plasma tumor necrosis factor-α concentration. Br J Haematol 1997;99:625-31. 8. G, Finazzi S, Maiolo AT. Folate measurement in patients on regular hemodialysis treatment. Am J Kidney Dis 1999; 33:492-7. 9. Trotti R, Carratelli M, Barbieri M, Micieli G, Bosone D, Rondanelli M, et al. Oxidative stress and a thrombophilic condition in alcoholics without severe liver disease. Haematologica 2001;86:85-91. 10. Lantos J, Roth E, Czopf L, Nemes J, Gal I. Monitoring of plasma total antioxidant status in different diseases. Acta Chir Hung 1997;36:188-9.
منابع مشابه
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
The aim of the present study was to compare thalidomide-dexamethasone (Thal-Dex) and vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous peripheral blood stem-cell (PBSC) transplantation for multiple myeloma (MM). For this purpose, we performed a retrospective matched case-control analysis of 200 patients who entered 2 consecutive studies from 1996 to 20...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
The aim of the present study was to compare thalidomide-dexamethasone (Thal-Dex) and vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous peripheral blood stem-cell (PBSC) transplantation for multiple myeloma (MM). For this purpose, we performed a retrospective matched case-control analysis of 200 patients who entered 2 consecutive studies from 1996 to 200...
متن کاملUpdates in the treatment of multiple myeloma.
The patient with multiple myeloma should be carefully evaluated from the standpoint of symptoms, physical findings, and laboratory data. If there are no symptoms or evidence of early or impending complications, the patient should not be treated. He or she should be followed and treatment delayed until progression of the disease occurs. If the patient is younger than 70 years, autologous periphe...
متن کاملSuccessful Treatment of Low-Dose Lenalidomide Maintenance Therapy Followed by Second Autologous Peripheral Blood Stem Cell Transplantation in Heavily Treated Multiple Myeloma
Recently, the prognosis of multiple myeloma has been improved by using high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (ASCT), bortezomib, and immunomodulatory drugs including thalidomide and lenalidomide. On the other hand, treatment strategy remains difficult for refractory and relapse cases. Here, we report the successful treatment of low-dose lenalid...
متن کاملThalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
In this issue of the Journal of Clinical Oncology, Rajkumar et al report on the results of a randomized phase III clinical trial of thalidomide plus dexamethasone compared to high-dose dexamethasone alone in newly diagnosed multiple myeloma. In this study, coordinated by the Eastern Cooperative Oncology Group, 207 patients were randomly assigned to either thalidomide plus dexamethasone or high-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Haematologica
دوره 88 5 شماره
صفحات -
تاریخ انتشار 2003